Spaceflight medical countermeasures: a strategic approach for mitigating effects from solar particle events

References

• Amgen. 2015. NEUPOGEN® (filgrastim) injection, for subcutaneous or intravenous use Initial U.S. Approval: 1991. Available from: https://www.pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.pdf
   Google Scholar
• Carnell LS, Blattnig S, Hu S, Huff J, Kim MH, Norman R, Patel Z, Simonsen L, Wu H. 2015. Evidence report: risk of acute radiation syndromes due to solar particle events. NASA Technical Report. JSC-CN-35747.
   Google Scholar
• Carnell LS. 2019. Medical Countermeasures: A Strategic Approach for Galactic Cosmic Radiation. NASA Technical Report. Hampton (VA): NASA Langley Research Center.
   Google Scholar
• Center for Disease Control and Prevention (CDC). 2019. Acute radiation syndrome: a fact sheet for clinicians. [accessed 2019 May 29]. https://www.cdc.gov/nceh/radiation/emergencies/arsphysicianfactsheet.htm.
   Google Scholar
• Crucian B, Babiak-Vazquez A, Johnston S, Pierson DL, Ott CM, Sams C. 2016. Incidence of clinical symptoms during long-duration orbital spaceflight. Int J Gen Med. 9:383–391.
   PubMed Web of Science ®Google Scholar
• Crucian BE, Choukèr A, Simpson RJ, Mehta S, Marshall G, Smith SM, Zwart SR, Heer M, Ponomarev S, Whitmire A, et al. 2018. Immune system dysregulation during spaceflight: potential countermeasures for deep space exploration missions. Front Immunol. 9:1437.
   PubMed Web of Science ®Google Scholar
• DiCarlo AL, Maher C, Hick JL, Hanfling D, Dainiak N, Chao N, Bader JL, Coleman CN, Weinstock DM. 2011. Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep. 5(Suppl 1):S32–S44.
   PubMed Web of Science ®Google Scholar
• FDA. 2015a. Neupogen. https://www.fda.gov/emergency-preparedness-and-response/about-mcmi/fda-approves-radiation-medical-countermeasure.
   Google Scholar
• FDA. 2015b. Neulasta. https://globalbiodefense.com/2015/12/03/pegfilgrastim-neulasta-acute-radiation-syndrome/.
   Google Scholar
• FDA. 2018. FDA approves leukine for acute radiation syndrome. https://www.fda.gov/media/112441/download.
   Google Scholar
• Homer MJ, Raulli R, DiCarlo-Cohen AL, Esker J, Hrdina C, Maidment BW, Moyer B, Rios C, Macchiarini F, Prasanna PG, et al. 2016. United States Department of health and human services biodosimetry and radiological/nuclear medical countermeasure programs. Radiat Prot Dosimetry. 171(1):85–98.
   PubMed Web of Science ®Google Scholar
• Hu S, Kim MY, McClellan GE, Cucinotta FA. 2009. Modelling the acute health effects of astronauts from exposure to large solar particle events. Health Phys. 96:465–476.
   PubMed Web of Science ®Google Scholar
• Kast J, Yu Y, Seubert CN, Wotring VE, Derendorf H. 2017. Drugs in space: pharmacokinetics and pharmacodynamics in astronauts. Eur J Pharm Sci. 109S:S2–S8.
   PubMedGoogle Scholar
• Kennedy AR. 2014. Biological effects of space radiation and development of effective countermeasures. Life Sci Space Res. 1:10–43.
   Google Scholar
• Kim MY, Hu S, Nounu HN, Cucinotta FA. 2010. Development of graphical user interface for ARRBOD (acute radiation risk and BRYNTRN organ dose projection). NASA/TP-2010-216116. Houston (TX): NASA Johnson Space Center.
   Google Scholar
• King GL, Rabin BM, Weatherspoon JK. 1999. 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation. Aviat Space Environ Med. 70(5):485–492.
   PubMedGoogle Scholar
• Marshburn TH. 2008. Acute care. In: Barrat MR and Pool SL, editors. Principles of clinical medicine for space flight. New York (NY): Springer-Verlag; p. 101–123.
   Google Scholar
• Meibohm B, Derendorf H. 1997. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther. 35(10):401–413.
   PubMed Web of Science ®Google Scholar
• Mettler FA. 2012. Medical effects and risks of exposure to ionising radiation. J Radiol Prot. 32(1):N9–N13.
   PubMed Web of Science ®Google Scholar
• NPR 8900.1A Appendix D: Transition to Operations Review Process (TORP). 2016 (Dec 16). NASA Procedural Requirements: NASA Health and Medical Requirements for Human Space Exploration.
   Google Scholar
• Romero-Weaver AL, Wan XS, Diffenderfer ES, Lin L, Kennedy AR. 2013. Effect of SPE-like proton or photon radiation on the kinetics of mouse peripheral blood cells and radiation biological effectiveness determinations. Astrobiology. 13(6):570–577.
   PubMed Web of Science ®Google Scholar
• Ryan JL. 2012. Ionizing radiation: the good, the bad, and the ugly. J Invest Dermatol. 132(3 Pt 2):985–993.
   PubMed Web of Science ®Google Scholar
• Simpson JA. 1983. Introduction to the galactic cosmic radiation. In: Shapiro MM, editors. Composition and origin of cosmic rays. NATO ASI Series (Series C: Mathematical and Physical Sciences). vol 107. Netherlands: Springer; p. 1–24.
   Google Scholar
• Singh VK, Romaine PLP, Seed TM. 2015. Medical countermeasures for radiation exposure and related injuries: characterization of medicines, FDA-approval status and inclusion into the strategic national stockpile. Health Phys. 108(6):607–630.
   PubMed Web of Science ®Google Scholar
• Singh VK, Garcia M, Seed TM. 2017. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. Int J Radiat Biol. 93(9):870–884.
   PubMed Web of Science ®Google Scholar
• Taddeo TA, Armstrong CW. 2008. Spaceflight medical systems. In: Barrat MR and Pool SL, editors. Principles of clinical medicine for space flight. New York (NY): Springer-Verlag; p. 69–101.
   Google Scholar
• Townsend L, Adams J, Blattnig S, Clowdsley M, Fry D, Jun I, McLeod C, Minow J, Moore D, Norbury J, et al. 2018. Solar particle event storm shelter requirements for missions beyond low Earth orbit. Life Sci Space Res. 17:32–39.
   Google Scholar
• Whitley HP, Lindsey W. 2009. Sex-based differences in drug activity. Am Fam Physician. 1(8011):1254–1258.
   Google Scholar